Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 71.4%High 1 · 14.3%

Anti‐VEGF vs control

BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 4.19 [2.32, 7.55]
6 studies · 2667 participants
Moderate

Anti‐VEGF vs control

Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment leads to higher loss of fewer than 15 letters visual acuity at 1 year compared with control (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.4 [1.27, 1.55]
6 studies · 2667 participants
High

Anti‐VEGF vs control

Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2508 participants
Moderate

Anti‐VEGF vs control

Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐VEGF vs control

Vision‐related quality of life · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
MD 6.69 [3.38, 9.99]
2 studies · 1134 participants
Moderate

Anti‐VEGF vs control

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.17 [0.01, 4.24]
6 studies · 2667 participants
Moderate

Anti‐VEGF vs control

Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 0.52 [0.03, 8.25]
6 studies · 2667 participants
Moderate